H.R.2672 - Preserving Access to Orphan Drugs Act of 2011

To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers. view all titles (2)

All Bill Titles

  • Official: To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers. as introduced.
  • Short: Preserving Access to Orphan Drugs Act of 2011 as introduced.

This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.

Bill’s Views

  • Today: 1
  • Past Seven Days: 1
  • All-Time: 1,726
 
Introduced
 
House
Passes
 
Senate
Passes
 
President
Signs
 

 
07/27/11
 
 
 
 
 
 
 

Sponsor

Representative

Jim Gerlach

R-PA

View Co-Sponsors (36)

Official Summary

Preserving Access to Orphan Drugs Act of 2011 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions fr

Official Summary

Preserving Access to Orphan Drugs Act of 2011 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million. Makes this Act effective as if included in PPACA.

...Read the Rest

Organizations Supporting H.R.2672

  • Plasma Protein Therapeutics Association
  • Immune Deficiency Foundation
  • Alpha 1 Foundation

Organizations Opposing H.R.2672

  • None via MapLight at this time.




Vote on This Bill

-% Users Support Bill

0 in favor / 0 opposed
 

Send Your Rep a Letter

about this bill Support Oppose Tracking
Track with MyOC